{
  "name": "Amgen",
  "slug": "amgen",
  "ticker": "AMGN",
  "fetched_at": "2025-11-13T12:24:23.872312+00:00",
  "news": [
    {
      "title": "Amgen’s (AMGN) Cholesterol Drug Is Very Important, Says JIm Cramer - Yahoo Finance",
      "link": "https://news.google.com/rss/articles/CBMihAFBVV95cUxNRGdNeEUya1hxdk44enkwZER3Qkt5UkZYaDJyM29IYXNZcWZXSlpqdEhDN1lGMWpvUUpOYWZIMzdNRmhJMmZubGNvaFcwMDR2V3B1XzVSSC1VTThJeFJqb3BCRl9DalNPZ1lWdjhqNFFEM19oeWJLY1VBQy12RzRUTG0xSW8?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMihAFBVV95cUxNRGdNeEUya1hxdk44enkwZER3Qkt5UkZYaDJyM29IYXNZcWZXSlpqdEhDN1lGMWpvUUpOYWZIMzdNRmhJMmZubGNvaFcwMDR2V3B1XzVSSC1VTThJeFJqb3BCRl9DalNPZ1lWdjhqNFFEM19oeWJLY1VBQy12RzRUTG0xSW8?oc=5\" target=\"_blank\">Amgen’s (AMGN) Cholesterol Drug Is Very Important, Says JIm Cramer</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Yahoo Finance</font>",
      "published": "2025-11-12T18:07:53+00:00",
      "source": "Yahoo Finance"
    },
    {
      "title": "CEO of drugmaker Amgen talks new results from cholesterol drug trial - CNBC",
      "link": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNWnIyMTBzWlF3YTBDeVhfYlNYcnZBZ2RzQWpOamRxb3JSZU55MEdrUDRqdzZGT2o3VGNxa05Pc21hUThTZW9pS3lSWmFNWHZfaXJ0YmNodTVXNFhjM2hYZjBWeVpkSlVCakJHczRtOV94aWt2VlJQaU8zQWxCenZvZ1cyVmlJUDJSQUwzd0xZallhcldodk1jUjdnRk5RbkY3VUNPb29fWjLSAa4BQVVfeXFMTndXUncyNjdFRlpKT21TbEFRV2pMY1lDeTdEQ3NNcFlzLV9ScTJJZjFGdDRTWElDbHNGRXkwSkFMVFBxZVFQZzVDRWZmYVlJcEYxOVR6dGtKcEpOVDBlWXRSQVVxSGFnMUxxd2pMaTNmWkZGeTBCMVhGZ0lNbkFzNUlmcGZETUtFTXJkX01qblFRSTFHUG9kV3hVa29yWkNXTjFOZkxuNzY5SjZ6REl3?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNWnIyMTBzWlF3YTBDeVhfYlNYcnZBZ2RzQWpOamRxb3JSZU55MEdrUDRqdzZGT2o3VGNxa05Pc21hUThTZW9pS3lSWmFNWHZfaXJ0YmNodTVXNFhjM2hYZjBWeVpkSlVCakJHczRtOV94aWt2VlJQaU8zQWxCenZvZ1cyVmlJUDJSQUwzd0xZallhcldodk1jUjdnRk5RbkY3VUNPb29fWjLSAa4BQVVfeXFMTndXUncyNjdFRlpKT21TbEFRV2pMY1lDeTdEQ3NNcFlzLV9ScTJJZjFGdDRTWElDbHNGRXkwSkFMVFBxZVFQZzVDRWZmYVlJcEYxOVR6dGtKcEpOVDBlWXRSQVVxSGFnMUxxd2pMaTNmWkZGeTBCMVhGZ0lNbkFzNUlmcGZETUtFTXJkX01qblFRSTFHUG9kV3hVa29yWkNXTjFOZkxuNzY5SjZ6REl3?oc=5\" target=\"_blank\">CEO of drugmaker Amgen talks new results from cholesterol drug trial</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">CNBC</font>",
      "published": "2025-11-10T23:39:59+00:00",
      "source": "CNBC"
    },
    {
      "title": "Amgen, Merck, Novo, More Take Cardiovascular Benefits to New Heights at AHA 2025 - BioSpace",
      "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNMmlvVnptRkd3aFc2MjZFbmNScUE0ZnNuNGJJc2pWSFZIWVdDbDZDcGFQcy1xaTlVT2tDSXpYbG5henhYZnVCcWpTWjB1RUhPbGliOHNWdWJnMU9YVFlOeXBZVFgzc05ycUkyY0FMYnRQN2gtR0s5Mm5IVTJoUDJIenByYjktQ1l5OHJ5LTN5Y21uOXhvLVJTdm1MemhDRzVicDR3UjNxbkphOVRvbG5Bb3RuTDkxOEtXZjRN?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNMmlvVnptRkd3aFc2MjZFbmNScUE0ZnNuNGJJc2pWSFZIWVdDbDZDcGFQcy1xaTlVT2tDSXpYbG5henhYZnVCcWpTWjB1RUhPbGliOHNWdWJnMU9YVFlOeXBZVFgzc05ycUkyY0FMYnRQN2gtR0s5Mm5IVTJoUDJIenByYjktQ1l5OHJ5LTN5Y21uOXhvLVJTdm1MemhDRzVicDR3UjNxbkphOVRvbG5Bb3RuTDkxOEtXZjRN?oc=5\" target=\"_blank\">Amgen, Merck, Novo, More Take Cardiovascular Benefits to New Heights at AHA 2025</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">BioSpace</font>",
      "published": "2025-11-11T14:27:17+00:00",
      "source": "BioSpace"
    },
    {
      "title": "Why Amgen Stock Was a Nearly 5% Winner Today - The Motley Fool",
      "link": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPQldkVERIcTlRaTVZbTdIWEFEMFhVMXdCS21OemJDb1VFZUhxQlhfUnpLV3ItbVB5alc3bHRYaWhPcmlMR3ZldUo0X0NOMEw1M2xUM0M3OUtfSEM0VmZEWElKUUs2ZFZrMEJhdHhpRGs3NnVNZUlBMFA4R0tTTkhZanVFeVdHVF9aLUdoSXliVQ?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMijwFBVV95cUxPQldkVERIcTlRaTVZbTdIWEFEMFhVMXdCS21OemJDb1VFZUhxQlhfUnpLV3ItbVB5alc3bHRYaWhPcmlMR3ZldUo0X0NOMEw1M2xUM0M3OUtfSEM0VmZEWElKUUs2ZFZrMEJhdHhpRGs3NnVNZUlBMFA4R0tTTkhZanVFeVdHVF9aLUdoSXliVQ?oc=5\" target=\"_blank\">Why Amgen Stock Was a Nearly 5% Winner Today</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">The Motley Fool</font>",
      "published": "2025-11-11T22:31:00+00:00",
      "source": "The Motley Fool"
    },
    {
      "title": "Amgen’s Repatha Cuts Risk of First Heart Attack by 36% in Phase III Trial - BioSpace",
      "link": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQaC13YU5WWXhqVGdFYzJRclU3NS1LUjg5US1fNGxFZzBmc0pNNmR3X1F2RHM5SlJhcVczQ0QxMWdudl9rd3R0clVLUmU2QXJfcGdSYThWOV9qRGhyN2ExcG1SSnRYVC1wcFNBanQ5aVRqZDFpM3E4UFZNNUJhMTNVc0QwOWpRMmFRa05ab0xBWW9EeU5XMjJnbmphcXFwVlJxeG1qQURZLXk5R0FyZVpadXdDMA?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiswFBVV95cUxQaC13YU5WWXhqVGdFYzJRclU3NS1LUjg5US1fNGxFZzBmc0pNNmR3X1F2RHM5SlJhcVczQ0QxMWdudl9rd3R0clVLUmU2QXJfcGdSYThWOV9qRGhyN2ExcG1SSnRYVC1wcFNBanQ5aVRqZDFpM3E4UFZNNUJhMTNVc0QwOWpRMmFRa05ab0xBWW9EeU5XMjJnbmphcXFwVlJxeG1qQURZLXk5R0FyZVpadXdDMA?oc=5\" target=\"_blank\">Amgen’s Repatha Cuts Risk of First Heart Attack by 36% in Phase III Trial</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">BioSpace</font>",
      "published": "2025-11-10T14:05:55+00:00",
      "source": "BioSpace"
    },
    {
      "title": "Where Does Amgen Stand After 15% Surge and New Pipeline Approvals in 2025? - Yahoo Finance",
      "link": "https://news.google.com/rss/articles/CBMie0FVX3lxTE1nbmNoakZwYl9XWjZvdXMydklaNzdfdERBZUtld2JGN2pjOXBkUnVoamdMVmtuRk1QMlN3N2kzWDU3RDdTejB1eFhkY0xhYW93b2xGN2R5cXlObjV0cWsyaE0wMjJtRVhLR0NfeGZySDFudUpsT0QtV3ItVQ?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMie0FVX3lxTE1nbmNoakZwYl9XWjZvdXMydklaNzdfdERBZUtld2JGN2pjOXBkUnVoamdMVmtuRk1QMlN3N2kzWDU3RDdTejB1eFhkY0xhYW93b2xGN2R5cXlObjV0cWsyaE0wMjJtRVhLR0NfeGZySDFudUpsT0QtV3ItVQ?oc=5\" target=\"_blank\">Where Does Amgen Stand After 15% Surge and New Pipeline Approvals in 2025?</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Yahoo Finance</font>",
      "published": "2025-11-13T03:16:00+00:00",
      "source": "Yahoo Finance"
    },
    {
      "title": "Elevance Health, Labcorp, Privia Health, Fortrea, and Amgen Shares Are Soaring, What You Need To Know - Yahoo Finance",
      "link": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxNdzRWRVUtZ0plU0xLdzlBTUNsUlM1ZEZFNzB5dGRLQVdSdkNPcnNJVFFyVGVPeGJPVGYwWlR6UjhkeXhUNUVfMnpCUWwtQmN4TnUzYTlsaFRLMnBkNk9FTk5nUWt1akh2X1BNZ1pLZHFDdXRORWJEZUp2Y2lTY0tDRkt0Unc5UEZWbWlR?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNdzRWRVUtZ0plU0xLdzlBTUNsUlM1ZEZFNzB5dGRLQVdSdkNPcnNJVFFyVGVPeGJPVGYwWlR6UjhkeXhUNUVfMnpCUWwtQmN4TnUzYTlsaFRLMnBkNk9FTk5nUWt1akh2X1BNZ1pLZHFDdXRORWJEZUp2Y2lTY0tDRkt0Unc5UEZWbWlR?oc=5\" target=\"_blank\">Elevance Health, Labcorp, Privia Health, Fortrea, and Amgen Shares Are Soaring, What You Need To Know</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Yahoo Finance</font>",
      "published": "2025-11-11T20:55:50+00:00",
      "source": "Yahoo Finance"
    },
    {
      "title": "Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance",
      "link": "https://news.google.com/rss/articles/CBMigAFBVV95cUxQY3BsNzNLeThiZ3N2Q1hZalIzZHRmNE9uRTZvQlJLSlNyWHBEaktqRDRlLWxVYmpYemVRcWhOTTlYb0NNYnRHWWpvSEZBX3J3UVluNk9FRHFUNTZ5cDBMS0pGaFVDQ3dUWjZsVXNLTE1sR2NlMVZaRnRKRmtJanhYZQ?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMigAFBVV95cUxQY3BsNzNLeThiZ3N2Q1hZalIzZHRmNE9uRTZvQlJLSlNyWHBEaktqRDRlLWxVYmpYemVRcWhOTTlYb0NNYnRHWWpvSEZBX3J3UVluNk9FRHFUNTZ5cDBMS0pGaFVDQ3dUWjZsVXNLTE1sR2NlMVZaRnRKRmtJanhYZQ?oc=5\" target=\"_blank\">Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Yahoo Finance</font>",
      "published": "2025-11-11T14:00:02+00:00",
      "source": "Yahoo Finance"
    }
  ],
  "product_launches": [
    {
      "title": "A Look at Amgen’s (AMGN) Valuation as Repatha Scores Major Trial Win and Direct Sales Launch Spurs Optimism - Yahoo Finance",
      "link": "https://news.google.com/rss/articles/CBMihgFBVV95cUxObWpGcHFxUm1WbnhhdFJUOW1kcjlGamhOQTdxdnVqWVRmQkxzNzdYd0poQk96QVByUENRMHhxQlFhVXctWGhjSWw4bjIzMXoxdFhLaVhpU0xMbnltTjhBejY4X1lQOWJuRENDNjVTbWxRRjZMMERRT0RVLVdETjhUcVljeTM3QQ?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMihgFBVV95cUxObWpGcHFxUm1WbnhhdFJUOW1kcjlGamhOQTdxdnVqWVRmQkxzNzdYd0poQk96QVByUENRMHhxQlFhVXctWGhjSWw4bjIzMXoxdFhLaVhpU0xMbnltTjhBejY4X1lQOWJuRENDNjVTbWxRRjZMMERRT0RVLVdETjhUcVljeTM3QQ?oc=5\" target=\"_blank\">A Look at Amgen’s (AMGN) Valuation as Repatha Scores Major Trial Win and Direct Sales Launch Spurs Optimism</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Yahoo Finance</font>",
      "published": "2025-10-16T07:00:00+00:00",
      "source": "Yahoo Finance"
    },
    {
      "title": "AMGN Q3 Deep Dive: Broad-Based Product Momentum and Pipeline Progress Drive Upbeat Guidance - TradingView",
      "link": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNN09XMkFVU05lZ0ZfVnZnbzkzU3NuNklBWEhsUWtkbVpTOHhHVHEzbk5PSEpGVEY1dUFjLTFLY3U5ZUg1RlhWZm1MR2hqNEd2ZWotTmx5T20wZjhseDBNcTdkdXlELXJvZjRZUVpDR1VXYTdtWmxHX3ZRLXFnRFBIb3VfWk4wSk5fV0ZoNGVSNFNhbkZqUHBhZXc2a0lQZ2Exa2w4eVJZakRFSk5uczBZcmJvSnlXVWRVNHQyV1M0MDZXd2l6X3dFbk5ua0p2UE1VUV9HV0xFS1ppLXZEdFJmRllmR1A1QQ?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMi5gFBVV95cUxNN09XMkFVU05lZ0ZfVnZnbzkzU3NuNklBWEhsUWtkbVpTOHhHVHEzbk5PSEpGVEY1dUFjLTFLY3U5ZUg1RlhWZm1MR2hqNEd2ZWotTmx5T20wZjhseDBNcTdkdXlELXJvZjRZUVpDR1VXYTdtWmxHX3ZRLXFnRFBIb3VfWk4wSk5fV0ZoNGVSNFNhbkZqUHBhZXc2a0lQZ2Exa2w4eVJZakRFSk5uczBZcmJvSnlXVWRVNHQyV1M0MDZXd2l6X3dFbk5ua0p2UE1VUV9HV0xFS1ppLXZEdFJmRllmR1A1QQ?oc=5\" target=\"_blank\">AMGN Q3 Deep Dive: Broad-Based Product Momentum and Pipeline Progress Drive Upbeat Guidance</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">TradingView</font>",
      "published": "2025-11-05T13:36:48+00:00",
      "source": "TradingView"
    },
    {
      "title": "Amgen, Kyowa Kirin Bolster Safety Profile for Atopic Dermatitis Hopeful - BioSpace",
      "link": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQVEJYNkQ0cURCVTNSd1VIbU1JLWtmblBqXzNDZnp6SVBBcWpGcm5zNWdaUFZwdjN4aGR4TnJoYm9PMWk2STRNdmdKMjRKU2pQVURtamRpUDBja3ZhYk1ONHJRemdtdkpVRHJ3SXBESkdyNG1hMW1ZQW4wb0xpYmMxY0E5RkRyVERkaS1FczJlUmZmbVZRN2VWenB5czdkeFg4eG5jNkZqQm9RU3FaMjl6dl9R?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMisgFBVV95cUxQVEJYNkQ0cURCVTNSd1VIbU1JLWtmblBqXzNDZnp6SVBBcWpGcm5zNWdaUFZwdjN4aGR4TnJoYm9PMWk2STRNdmdKMjRKU2pQVURtamRpUDBja3ZhYk1ONHJRemdtdkpVRHJ3SXBESkdyNG1hMW1ZQW4wb0xpYmMxY0E5RkRyVERkaS1FczJlUmZmbVZRN2VWenB5czdkeFg4eG5jNkZqQm9RU3FaMjl6dl9R?oc=5\" target=\"_blank\">Amgen, Kyowa Kirin Bolster Safety Profile for Atopic Dermatitis Hopeful</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">BioSpace</font>",
      "published": "2025-09-10T07:00:00+00:00",
      "source": "BioSpace"
    },
    {
      "title": "A Look at Amgen’s (AMGN) Valuation Following FDA Nod Expanding Repatha’s Patient Reach - simplywall.st",
      "link": "https://news.google.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?oc=5",
      "summary": "<a href=\"https://news.google.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?oc=5\" target=\"_blank\">A Look at Amgen’s (AMGN) Valuation Following FDA Nod Expanding Repatha’s Patient Reach</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">simplywall.st</font>",
      "published": "2025-09-08T07:00:00+00:00",
      "source": "simplywall.st"
    },
    {
      "title": "Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns - Seeking Alpha",
      "link": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNNldFcDdyVUNrRFhsN2JMUDZuakRJNDN5R0JBNzFfbXNuaGVLVTRubVhsV3l2eEk4MGR2X2xLcXVON3NHVVZOVjZvZHNzdHBsTGVNZEFJaEp2WGRxUnNYdng4TS1yaWNrd1g5bW5tcnNvZUh1QzlleW96akRZUG1tNGRKLXdqdmg5TUdudlpielVzcHd2VUpYa3pfWkJjX0lESEJDc3BET1hFWGtreWdqNEdkNlMtT2dncThfMVVuOA?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMivwFBVV95cUxNNldFcDdyVUNrRFhsN2JMUDZuakRJNDN5R0JBNzFfbXNuaGVLVTRubVhsV3l2eEk4MGR2X2xLcXVON3NHVVZOVjZvZHNzdHBsTGVNZEFJaEp2WGRxUnNYdng4TS1yaWNrd1g5bW5tcnNvZUh1QzlleW96akRZUG1tNGRKLXdqdmg5TUdudlpielVzcHd2VUpYa3pfWkJjX0lESEJDc3BET1hFWGtreWdqNEdkNlMtT2dncThfMVVuOA?oc=5\" target=\"_blank\">Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Seeking Alpha</font>",
      "published": "2025-07-15T07:00:00+00:00",
      "source": "Seeking Alpha"
    }
  ],
  "stock": {
    "ticker": "AMGN",
    "currency": "USD",
    "latest": {
      "date": "2025-11-12",
      "close": 336.2799987792969
    },
    "history": [
      {
        "date": "2025-11-04",
        "close": 296.70001220703125
      },
      {
        "date": "2025-11-05",
        "close": 319.8599853515625
      },
      {
        "date": "2025-11-06",
        "close": 315.5899963378906
      },
      {
        "date": "2025-11-07",
        "close": 320.20001220703125
      },
      {
        "date": "2025-11-10",
        "close": 323.6600036621094
      },
      {
        "date": "2025-11-11",
        "close": 338.45001220703125
      },
      {
        "date": "2025-11-12",
        "close": 336.2799987792969
      }
    ],
    "name": "Amgen Inc."
  }
}